

EXHIBIT C



UNITED STATES | ENGLAND | GERMANY | CHINA

October 29, 2007

By E-Mail and Fax

Laura Brandenburg, Esq.
Levin Simes Kaiser & Gornick, LLP
44 Montgomery, 36th Floor
San Francisco, CA 94104

Re: Seroquel MDL/Challenge to Confidentiality of Disclosures for Thomas, Coppola,
James, Glover, Naramore, and Godfrey

Dear Laura:

Responding to your e-mail of October 17, 2007, AstraZeneca addresses the challenges to the confidentiality of the categories of information included within its MDL case-specific disclosures as follows:

1) Call Notes: It is AstraZeneca's position that call notes are properly protected as confidential information. The call notes database is a proprietary database owned by or licensed to AstraZeneca and used only within AstraZeneca. Any dissemination of the structure, organization, or categories of information tracked in the database could provide competitors with a distinct advantage. Call notes are internal documents that describe the sales person's experience with each physician, including notes of discussions with each physician. This information is particularly confidential and is only used for internal purposes. Call notes are never publicly disseminated as they could provide competitors with a distinct advantage. Thus, AstraZeneca is not willing to de-designate these documents.

2) Payments to Doctors: It is AstraZeneca's position that information regarding payments to doctors are properly protected as confidential information. There are privacy and commercial concerns regarding these payments. Certain payments reflect physicians' participation in AstraZeneca's clinical trial programs. This information, to the extent it reveals details about AstraZeneca's clinical trial program, is particularly confidential and is only used for internal purposes. Thus, AstraZeneca is not willing to de-designate these documents.

3) IMS Data: It is AstraZeneca's position that IMS data is properly protected as confidential information. This data is not publicly disseminated or publicly available, and

Laura Brandenburg, Esq.
October 29, 2007


is only used for internal purposes. Furthermore, IMS Health, Inc. has specifically requested, and Plaintiffs have agreed, that this data be maintained as confidential. Thus, AstraZeneca is not willing to de-designate this information.

4) Dear Doctor Letters Received by Particular Physician: AstraZeneca is willing to agree to de-designate information confirming that any such letters were sent to a particular physician in its MDL case-specific disclosures.

5) PIRs: Because patient-identifying information is not contained within its PIR responses, AstraZeneca is willing to agree to de-designate PIR responses produced as part of its MDL case-specific disclosures.

Please contact me if you have any questions.

Very truly yours,

A handwritten signature in black ink, appearing to read "Russell Stewart". The signature is written in a cursive style with a large, sweeping initial "R".

Russell Stewart

cc: Buffy Martines, Esq.